Compare · BGXX vs DFTX
BGXX vs DFTX
Side-by-side comparison of Bright Green Corporation (BGXX) and Definium Therapeutics Inc. (DFTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BGXX and DFTX operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX carries a market cap of $6.02B.
- DFTX has hit the wire 15 times in the past 4 weeks while BGXX has been quiet.
- DFTX has more recent analyst coverage (7 ratings vs 0 for BGXX).
- Company
- Bright Green Corporation
- Definium Therapeutics Inc.
- Price
- $0.14-30.63%
- $44.77+3.55%
- Market cap
- -
- $6.02B
- 1M return
- -
- +4.98%
- 1Y return
- -
- +349.00%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 0
- 15
- Recent ratings
- 0
- 7
Latest BGXX
- Lynn Stockwell and Bright Green Corporation File $3 Billion Lawsuit Against Rodey Law Firm and Attorneys' Liability Assurance Society (ALAS) for Legal Malpractice and Bad Faith
- PharmAGRI Capital Partners Targets $10 Billion Federal Procurement Opportunity for Onshored Plant-Based Prescription Drugs Bright Green Corporation "BGXXQ" Q and A
- Bright Green Corporation Merges with PharmAGRI Capital Partners; Lynn Stockwell Appointed CEO and Chairwoman
- SEC Form 25-NSE filed by Bright Green Corporation
- Bright Green Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Bright Green Corporation Announces the next steps for the completion of its restructuring plan
- Bright Green Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Financial Statements and Exhibits
- Bright Green Corporation Announces the completion of its restructuring plan, withdraws from the Cannabis business and sets course on the production of all DEA Scheduled Controlled Substances
- Bright Green Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Financial Statements and Exhibits
- Bright Green Corporation Has Signed Agreement with Majority Shareholder as Plan Sponsor on Prepackaged Plan to Restructure the Company.
Latest DFTX
- BofA Securities initiated coverage on Definium Therapeutics with a new price target
- Definium Therapeutics Announces New Employee Inducement Grants
- Amendment: SEC Form SCHEDULE 13G/A filed by Definium Therapeutics Inc.
- Chief Commercial Officer Wiley Matthew T. was granted 62,500 shares, increasing direct ownership by 36% to 237,133 units (SEC Form 4)
- Chief Medical Officer Karlin Daniel was granted 100,000 shares, increasing direct ownership by 20% to 603,282 units (SEC Form 4)
- Chief Financial Officer Roberts Brandi was granted 62,500 shares, increasing direct ownership by 30% to 271,987 units (SEC Form 4)
- Chief Executive Officer Barrow Robert was granted 375,000 shares, increasing direct ownership by 34% to 1,473,246 units (SEC Form 4)
- Chief Legal Officer Sullivan Mark was granted 62,500 shares, increasing direct ownership by 19% to 383,071 units (SEC Form 4)
- Definium Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Definium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study of DT120 ODT in Generalized Anxiety Disorder